View Older Stories View More Recent Stories

Jun 17, 2022 07:05AM Acadia Pharmaceuticals Stock Trading Halted Today
May 4, 2022 04:05PM Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022 04:05PM Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 2, 2022 04:06PM Acadia Pharma (ACAD) Announces FDA Advisory Committee Meeting to Review Resubmission of sNDA for NUPLAZID for Treatment of Alzheimer’s Disease Psychosis
May 2, 2022 04:05PM Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psy
Apr 21, 2022 09:00AM Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
Apr 19, 2022 09:24AM Pre-Open Stock Movers 04/19: Super Micro and American Campus Higher; NETGEAR and Stellantis Lower (more...)
Apr 18, 2022 06:07PM After-Hours Stock Movers 04/18: Super Micro and Griffon Higher; NETGEAR and Acadia Lower (more...)
Apr 18, 2022 04:05PM Acadia Pharma (ACAD) Reports Phase 2 Study of ACP-044 Did Not Meet Primary Endpoint
Apr 18, 2022 04:05PM Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
Mar 22, 2022 09:00AM Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
Mar 10, 2022 04:05PM Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
Mar 9, 2022 08:30AM Acadia Pharma (ACAD) Announces August 4, 2022 Action Date for Resubmitted SNDA for NUPLAZID in Alzheimer’s Disease Psychosis
Mar 9, 2022 08:30AM Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
Mar 3, 2022 09:00AM Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
Feb 28, 2022 04:05PM Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 16, 2022 09:03AM Acadia Pharma (ACAD) Resubmits Supplemental New Drug Application to U.S. FDA for NUPLAZID to Treat Alzheimer’s Disease Psychosis
Feb 16, 2022 09:00AM Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
Feb 14, 2022 09:00AM Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
Feb 11, 2022 09:00AM Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
Jan 10, 2022 07:06AM Acadia Pharma (ACAD), Stoke Therapeutics (STOK) Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Jan 10, 2022 07:00AM Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Dec 22, 2021 09:00AM Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Dec 20, 2021 04:05PM Acadia Pharma (ACAD) Plans to Resubmit Supplemental New Drug Application to U.S. FDA for NUPLAZID
Dec 20, 2021 04:05PM Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
Dec 14, 2021 09:06AM Acadia Pharma (ACAD) Promotes Mark Schneyer to CFO, Executive VP
Dec 14, 2021 09:00AM Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
Dec 6, 2021 04:08PM Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Dec 6, 2021 04:05PM Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Dec 1, 2021 09:02AM Acadia Pharma (ACAD) Announces Publication of Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
Dec 1, 2021 09:00AM The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
Nov 16, 2021 09:00AM Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
Nov 8, 2021 04:05PM Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
Nov 2, 2021 09:00AM Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
Nov 1, 2021 04:05PM Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
Oct 27, 2021 09:00AM Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
Oct 25, 2021 09:00AM Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD)
Sep 1, 2021 04:05PM Acadia Pharmaceuticals Announces Executive Leadership Change
Aug 5, 2021 04:05PM Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
Aug 4, 2021 04:05PM Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
Jul 21, 2021 05:05PM The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
Jul 21, 2021 09:00AM Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
Jul 14, 2021 09:00AM Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
Jun 25, 2019 08:50AM New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
Nov 14, 2016 07:49AM JANA Partners Enters Kate Spade (KATE), Select Medical (SEM), Twitter (TWTR) (more...)
Oct 11, 2016 09:00AM ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
Mar 29, 2016 10:14AM Acadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA Panel
Feb 1, 2016 09:19AM Pre-Open Stock Movers 02/01: (ALR) (STR) (TROV) Higher; (GPRO) (TSLA) (D) Lower (more...)
Mar 16, 2015 10:01AM Acadia Pharmaceuticals Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
View More Recent Stories View Older Stories